Rakovina Therapeutics Inc. (TSXV:RKV)
Canada · Delayed Price · Currency is CAD | Market Cap | 11.37M +31.1% |
| Revenue (ttm) | n/a |
| Net Income | -7.01M |
| EPS | -0.32 |
| Shares Out | 44.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,858 |
| Open | 0.2600 |
| Previous Close | 0.2450 |
| Day's Range | 0.2550 - 0.2600 |
| 52-Week Range | 0.0850 - 0.4200 |
| Beta | -0.10 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 1, 2026 |
About Rakovina Therapeutics
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase; and kt-4000 series, which are small molecules engineered to induce targeted DNA damage in tumor c... [Read more]
Financial Performance
Financial StatementsNews
Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharm...
Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement
Financing completed at the full upsized amount following strong investor demand Financing completed at the full upsized amount following strong investor demand
Rakovina Therapeutics Announces Results from 2026 Annual General Meeting
VANCOUVER, British Columbia, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered...
Rakovina Therapeutics Announces $1.5 Million Private Placement
VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)( FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial...
Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharm...
Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, April 30, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7J0), a biopharmaceutical company advancing next-generation ...
Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting
AI-Designed Dual ATR-mTOR Inhibitor Demonstrates In Vivo Efficacy; Novel LNP Formulation of Bifunctional PARP/HDAC Inhibitor kt-3283 Successfully Characterized AI-Designed Dual ATR-mTOR Inhibitor Demo...
Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 – World's Premier Cancer Research Forum
VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial...
Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement
VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cance...
Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements
VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cance...
Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million
Proposed $1.0 Million Convertible Debenture and Warrant Financing and Concurrent Common Share Private Placement Up to $1.0 Million Intended to Support Near-Term Operations
Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
Highlights: Strategic Validation: Industry feedback confirms Rakovina's approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-s...
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California
VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cance...
Rakovina Therapeutics Announces Upcoming Webinar with Variational AI
From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer Therapies From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Cod...
Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated.
Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program
VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies t...
Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting
Data highlights progress in Rakovina's AI-derived PARP-1 inhibitor program Data highlights progress in Rakovina's AI-derived PARP-1 inhibitor program
Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
VANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies t...
Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference
VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) is pleased to announce the successful presentation of ne...
Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV, FSE: 7JO0), a biopharmaceutical company advancing cancer therapies ...
Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapie...
Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated All dollar amounts reflected in Canadian dollars unless otherwise stated
Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis
VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies...
Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies
KT-3283, a dual PARP-HDAC inhibitor, to serve as first development program in NanoPalm's strategic expansion into the oncology field KT-3283, a dual PARP-HDAC inhibitor, to serve as first development ...
Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre
VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies...